LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders
Double-blind, placebo-controlled randomized crossover (n=46) testing two single-dose LSD 200 µg sessions versus two placebo sessions in patients with anxiety with or without life-threatening illness.
Details
This randomized, double-blind, placebo-controlled crossover trial evaluated the efficacy of LSD for anxiety in patients with or without advanced life-threatening illness, building on earlier pilot work suggesting anxiolytic effects.
Participants received two single doses of LSD 200 µg and two matching placebo sessions in randomized order; subjects served as their own controls with outcomes assessed at 2, 8, and 16 weeks post-treatment.
Primary outcomes included reduction in anxiety (STAI); secondary measures included HDRS, BDI and SCL-90 to evaluate depressive and general psychopathological symptoms.